Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy.

Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy. Drug Deliv. 2018 Nov;25(1):807-814 Authors: Yang J, Lv Q, Wei W, Yang Z, Dong J, Zhang R, Kan Q, He Z, Xu Y Abstract The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic efficiencies of small-molecule drugs. In this work, two novel oxidative/reductive (Ox/Re) -sensitive and one non-sensitive Paclitaxel (PTX) prodrugs were synthesized with a maleimide group, which rapidly conjugates with albumin in vivo. Albumin serves as a good vehicle to deliver more prodrug to tumors due to the enhanced permeation and retention (EPR) effect. PTX was then released from the prodrugs in glutathione(GSH)/ reactive oxygen species(ROS)-rich tumor microenvironments. This bioresponsive prodrug strategy demonstrates potent chemotherapeutic efficiency in vivo and may be utilized in clinical cancer therapy. PMID: 29553858 [PubMed - in process]
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research